From Financial Modeling Prep: 2024-11-08 09:00:04

In its recent earnings report, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) reported an EPS of -$0.15681, slightly better than the estimated -$0.16, showing progress in reducing losses. However, revenue of $18.46 million fell short of the estimated $23.26 million, revealing challenges in meeting revenue expectations. Despite this, the company maintains a strong current ratio of 3.92 and a low debt-to-equity ratio of 0.012, providing some financial stability.



Read more at Financial Modeling Prep:: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Financial …